Literature DB >> 19765461

Living related liver transplantation in Crigler-Najjar syndrome type 1.

F Ozçay1, F Alehan, S Sevmiş, H Karakayali, G Moray, A Torgay, G Arslan, M Haberal.   

Abstract

Four children underwent living related liver transplantation because of Crigler-Najjar syndrome type 1. Three were infants aged 2, 8(1/2), and 15 months, and weighed 5, 8, and 10 kg, respectively. Pretransplantation unconjugated bilirubin concentration was 22 to 30 mg/dL despite 12 to 14 hours of phototherapy daily. Patient 1, the 2-month-old infant, with unconjugated bilirubin concentration of 30 mg/dL, had a high-pitched cry, suggestive of bilirubin encephalopathy; results of neurologic examination were normal. Plasmapheresis and urgent liver transplantation were performed. Patient 4, a 13-year-old girl, had learning difficulties at school and attended a special class. Three patients received left lateral liver segments, and 1 patient received a left lobe. Biliary reconstruction was completed with duct-to-duct anastomosis. Bile leakage developed at the anastomosis in 2 patients, which was treated successfully with cholangioplasty. In all patients, the unconjugated bilirubin concentration normalized by day 1 posttransplantation, and no phototherapy was necessary. After transplantation, the 2-month-old infant with suspected encephalopathy exhibited hypotonia, spasticity of the lower extremities, and lack of head control. He died after vomitus aspiration during sleep at 10 months posttransplantation. The other 3 patients are alive with normal neurodevelopmental milestones. Irreversible brain damage may occur early in the course of Crigler-Najjar syndrome type 1. Urgent treatment including plasmapheresis, exchange transfusion, phototherapy, and liver transplantation may not reverse brain damage. Young infants must be evaluated carefully for subtle signs and symptoms of bilirubin encephalopathy. Liver transplantation is curative if performed before development of neurologic dysfunction.

Entities:  

Mesh:

Year:  2009        PMID: 19765461     DOI: 10.1016/j.transproceed.2009.07.025

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors.

Authors:  David Dimmock; Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; Philip Ng
Journal:  Hum Gene Ther       Date:  2011-02-16       Impact factor: 5.695

2.  Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.

Authors:  Kevin A Strauss; Charles E Ahlfors; Kyle Soltys; George V Mazareigos; Millie Young; Lauren E Bowser; Michael D Fox; James E Squires; Patrick McKiernan; Karlla W Brigatti; Erik G Puffenberger; Vincent J Carson; Hendrik J Vreman
Journal:  Hepatology       Date:  2020-02-05       Impact factor: 17.425

Review 3.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

4.  Acute cholangitis in an old patient with Crigler-Najjar syndrome type II - a case report.

Authors:  Samuel Raimundo Fernandes; Carlos Miguel Moura; Beatriz Rodrigues; Luís Araújo Correia; Helena Cortez-Pinto; José Velosa
Journal:  BMC Gastroenterol       Date:  2016-03-11       Impact factor: 3.067

5.  Amelioration of Hyperbilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes.

Authors:  Yong Chen; Yanfeng Li; Xia Wang; Wei Zhang; Vanessa Sauer; Chan-Jung Chang; Bing Han; Tatyana Tchaikovskaya; Yesim Avsar; Edgar Tafaleng; Sanal Madhusudana Girija; Krisztina Tar; Zsuzsanna Polgar; Stephen Strom; Eric E Bouhassira; Chandan Guha; Ira J Fox; Jayanta Roy-Chowdhury; Namita Roy-Chowdhury
Journal:  Stem Cell Reports       Date:  2015-06-11       Impact factor: 7.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.